

Tomoki Naoe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10405504/publications.pdf>

Version: 2024-02-01

163
papers

20,409
citations

20759

60
h-index

10424

139
g-index

166
all docs

166
docs citations

166
times ranked

20155
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447. | 0.6 | 4,375 |
| 2 | Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474. | 0.6 | 2,963 |
| 3 | Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2009, 113, 1875-1891. | 0.6 | 856 |
| 4 | let-7 MicroRNA Functions as a Potential Growth Suppressor in Human Colon Cancer Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 903-906. | 0.6 | 583 |
| 5 | Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. <i>Oncogene</i> , 2000, 19, 624-631. | 2.6 | 505 |
| 6 | High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL ⁺ Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 460-466. | 0.8 | 430 |
| 7 | Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients. <i>Clinical Cancer Research</i> , 2007, 13, 5124-5132. | 3.2 | 409 |
| 8 | Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643. | 0.6 | 393 |
| 9 | Downregulation of microRNAs ⁻¹⁴³ and ⁻¹⁴⁵ in B ⁺ cell malignancies. <i>Cancer Science</i> , 2007, 98, 1914-1920. | 1.7 | 271 |
| 10 | Presentation and management of intravascular large B-cell lymphoma. <i>Lancet Oncology</i> , The, 2009, 10, 895-902. | 5.1 | 267 |
| 11 | Decreased Expression of MicroRNA-143 and -145 in Human Gastric Cancers. <i>Oncology</i> , 2009, 77, 12-21. | 0.9 | 266 |
| 12 | Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. <i>Oncogene</i> , 2002, 21, 2555-2563. | 2.6 | 257 |
| 13 | Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan. <i>Journal of Clinical Oncology</i> , 2008, 26, 3189-3195. | 0.8 | 250 |
| 14 | Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. <i>Blood</i> , 2005, 106, 2854-2861. | 0.6 | 247 |
| 15 | Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. <i>Blood</i> , 2004, 103, 1901-1908. | 0.6 | 232 |
| 16 | Target Antigen Density Governs the Efficacy of Anti ⁺ CD20-CD28-CD3 ⁺ Chimeric Antigen Receptor ⁺ Modified Effector CD8 ⁺ T Cells. <i>Journal of Immunology</i> , 2015, 194, 911-920. | 0.4 | 228 |
| 17 | Microvesicle-mediated RNA Molecule Delivery System Using Monocytes/Macrophages. <i>Molecular Therapy</i> , 2011, 19, 395-399. | 3.7 | 225 |
| 18 | Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. <i>Blood</i> , 2011, 117, 2358-2365. | 0.6 | 218 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. <i>Blood</i> , 2009, 113, 4885-4893. | 0.6 | 217 |
| 20 | MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. <i>Oncology Reports</i> , 2006, 16, 845-50. | 1.2 | 212 |
| 21 | MicroRNA-143 and -145 in Colon Cancer. <i>DNA and Cell Biology</i> , 2007, 26, 311-320. | 0.9 | 205 |
| 22 | Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. <i>Nature Genetics</i> , 2016, 48, 569-574. | 9.4 | 198 |
| 23 | Integrin Activation and Matrix Binding Mediate Cellular Responses to Mechanical Stretch. <i>Journal of Biological Chemistry</i> , 2005, 280, 16546-16549. | 1.6 | 194 |
| 24 | Treatment With a New Synthetic Retinoid, Am80, of Acute Promyelocytic Leukemia Relapsed From Complete Remission Induced by All-trans Retinoic Acid. <i>Blood</i> , 1997, 90, 967-973. | 0.6 | 181 |
| 25 | Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. <i>Blood</i> , 2004, 104, 3507-3512. | 0.6 | 173 |
| 26 | Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission. <i>Cancer</i> , 2005, 103, 1652-1658. | 2.0 | 169 |
| 27 | A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR α transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. <i>Blood</i> , 2007, 110, 59-66. | 0.6 | 158 |
| 28 | Characterized mechanism of α -mangostin-induced cell death: Caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5620-5628. | 1.4 | 155 |
| 29 | A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSC AML201 Study. <i>Blood</i> , 2011, 117, 2366-2372. | 0.6 | 155 |
| 30 | Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As ₂ O ₃) in acute promyelocytic leukemia. <i>International Journal of Hematology</i> , 2013, 97, 717-725. | 0.7 | 151 |
| 31 | Identification of a Polymorphic Gene, BCL2A1, Encoding Two Novel Hematopoietic Lineage-specific Minor Histocompatibility Antigens. <i>Journal of Experimental Medicine</i> , 2003, 197, 1489-1500. | 4.2 | 150 |
| 32 | Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2014, 1839, 1256-1272. | 0.9 | 134 |
| 33 | Arsenic induces apoptosis in B α cell leukaemic cell lines in vitro : activation of caspases and down-regulation of Bcl-2 protein. <i>British Journal of Haematology</i> , 1998, 102, 1055-1060. | 1.2 | 129 |
| 34 | MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. <i>Cancer Letters</i> , 2011, 307, 211-220. | 3.2 | 129 |
| 35 | Adipose Tissue-Derived Mesenchymal Stem Cells Facilitate Hematopoiesis in Vitro and in Vivo. <i>American Journal of Pathology</i> , 2010, 177, 547-554. | 1.9 | 113 |
| 36 | Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. <i>European Journal of Haematology</i> , 2007, 78, 213-219. | 1.1 | 112 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Small molecule Hedgehog inhibitor attenuates the leukemia initiation potential of acute myeloid leukemia cells. <i>Cancer Science</i> , 2016, 107, 1422-1429. | 1.7 | 109 |
| 38 | KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. <i>Blood</i> , 2009, 114, 1607-1617. | 0.6 | 108 |
| 39 | Central nervous system involvement in intravascular large B cell lymphoma: A retrospective analysis of 109 patients. <i>Cancer Science</i> , 2010, 101, 1480-1486. | 1.7 | 107 |
| 40 | Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. <i>Blood</i> , 2011, 118, 1600-1609. | 0.6 | 105 |
| 41 | A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. <i>Blood</i> , 2018, 131, 426-438. | 0.6 | 104 |
| 42 | Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. <i>British Journal of Haematology</i> , 1999, 104, 659-664. | 1.2 | 101 |
| 43 | Randomized study of individualized induction therapy with or without vincristine, and of maintenance intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 study of the Japan adult leukemia study group. <i>Cancer</i> , 1993, 71, 3888-3895. | 2.0 | 95 |
| 44 | Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. <i>Life Sciences</i> , 2002, 70, 2253-2269. | 2.0 | 94 |
| 45 | Ectopic Expression of MAFB Gene in Human Myeloma Cells Carrying (14;20)(q32;q11) Chromosomal Translocations. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 638-644. | 1.7 | 88 |
| 46 | Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. <i>Oncogene</i> , 2003, 22, 9176-9184. | 2.6 | 86 |
| 47 | Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-transretinoic acid. <i>British Journal of Haematology</i> , 2000, 108, 696-702. | 1.2 | 84 |
| 48 | Prospective monitoring of <i>BCR-ABL1</i> transcript levels in patients with Philadelphia chromosome positive acute lymphoblastic leukaemia undergoing imatinib combined chemotherapy. <i>British Journal of Haematology</i> , 2008, 143, 503-510. | 1.2 | 84 |
| 49 | Phase I study of OPB-1602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. <i>Cancer Science</i> , 2015, 106, 896-901. | 1.7 | 83 |
| 50 | BCR-ABL-transformed GMP as myeloid leukemic stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17967-17972. | 3.3 | 81 |
| 51 | Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. <i>Blood</i> , 2003, 102, 2969-2975. | 0.6 | 80 |
| 52 | Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. <i>Leukemia Research</i> , 2009, 33, 1530-1538. | 0.4 | 80 |
| 53 | Identification of non-coding RNAs embracing microRNA-143/145 cluster. <i>Molecular Cancer</i> , 2010, 9, 136. | 7.9 | 75 |
| 54 | BMI-1 Is Highly Expressed in M0-Subtype Acute Myeloid Leukemia. <i>International Journal of Hematology</i> , 2005, 82, 42-47. | 0.7 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Tumor-suppressive microRNA-145 targets catenin β -1 to regulate Wnt/ β -catenin signaling in human colon cancer cells. <i>Cancer Letters</i> , 2013, 335, 332-342. | 3.2 | 72 |
| 56 | Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. <i>Blood</i> , 2013, 121, 3095-3102. | 0.6 | 70 |
| 57 | Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 1998, 101, 521-528. | 1.2 | 69 |
| 58 | Nucleophosmin: A versatile molecule associated with hematological malignancies. <i>Cancer Science</i> , 2006, 97, 963-969. | 1.7 | 65 |
| 59 | FLT3 in Human Hematologic Malignancies. <i>Leukemia and Lymphoma</i> , 2002, 43, 1541-1547. | 0.6 | 64 |
| 60 | Acute myeloid leukemia in older adults. <i>International Journal of Hematology</i> , 2012, 96, 186-193. | 0.7 | 64 |
| 61 | Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBF β -MYH11. <i>Blood Advances</i> , 2020, 4, 66-75. | 2.5 | 63 |
| 62 | Biology, Clinical Relevance, and Molecularly Targeted Therapy in Acute Leukemia with FLT3 Mutation. <i>International Journal of Hematology</i> , 2006, 83, 301-308. | 0.7 | 60 |
| 63 | Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. <i>Haematologica</i> , 2008, 93, 287-290. | 1.7 | 59 |
| 64 | Gene mutations of acute myeloid leukemia in the genome era. <i>International Journal of Hematology</i> , 2013, 97, 165-174. | 0.7 | 56 |
| 65 | In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi-scid/scid Mice. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 529-536. | 1.7 | 53 |
| 66 | Chemically Modified Synthetic microRNA-205 Inhibits the Growth of Melanoma Cells In Vitro and In Vivo. <i>Molecular Therapy</i> , 2013, 21, 1204-1211. | 3.7 | 53 |
| 67 | Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3729-3735. | 0.8 | 53 |
| 68 | DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2013, 1829, 1102-1110. | 0.9 | 52 |
| 69 | Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RAR α as a component of the N-CoR co-repressor complex to repress transcription in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 1471-1480. | 1.0 | 48 |
| 70 | Phase I study of glasdegib (CG04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies. <i>Cancer Science</i> , 2017, 108, 1628-1633. | 1.7 | 47 |
| 71 | Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. <i>Leukemia Research</i> , 2018, 66, 20-27. | 0.4 | 44 |
| 72 | Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy. <i>International Journal of Hematology</i> , 2007, 86, 49-57. | 0.7 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Mesenchymal Stem Cells Stably Transduced with a Dominant-Negative Inhibitor of CCL2 Greatly Attenuate Bleomycin-Induced Lung Damage. <i>American Journal of Pathology</i> , 2011, 179, 1088-1094. | 1.9 | 43 |
| 74 | CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). <i>Leukemia Research</i> , 2013, 37, 1021-1026. | 0.4 | 43 |
| 75 | Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 48-53. | 1.0 | 42 |
| 76 | Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia Jurkat cells by modulating expression of Fas-associated protein with death domain (FADD). <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 590-602. | 1.9 | 42 |
| 77 | Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2008, 140, 394-401. | 1.2 | 41 |
| 78 | Comprehensive analysis of cooperative gene mutations between class I and class II in <i>de novo</i> acute myeloid leukemia. <i>European Journal of Haematology</i> , 2009, 83, 90-98. | 1.1 | 41 |
| 79 | Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells. <i>Japanese Journal of Cancer Research</i> , 2000, 91, 1154-1160. | 1.7 | 39 |
| 80 | Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. <i>International Journal of Hematology</i> , 2008, 88, 149-153. | 0.7 | 39 |
| 81 | Clonal Analysis of Multiple Point Mutations in the N-rasGene in Patients with Acute Myeloid Leukemia. <i>Japanese Journal of Cancer Research</i> , 1993, 84, 379-387. | 1.7 | 38 |
| 82 | Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice. <i>Leukemia and Lymphoma</i> , 2006, 47, 1747-1753. | 0.6 | 38 |
| 83 | Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. <i>Cancer Science</i> , 2015, 106, 1590-1595. | 1.7 | 37 |
| 84 | Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. <i>Annals of Hematology</i> , 2018, 97, 1535-1545. | 0.8 | 37 |
| 85 | Novel heterozygous missense mutation in the platelet glycoprotein Ib β gene associated with isolated giant platelet disorder. <i>American Journal of Hematology</i> , 2001, 68, 249-255. | 2.0 | 36 |
| 86 | Antitumor effect of arsenic trioxide in murine xenograft model. <i>Cancer Science</i> , 2003, 94, 1010-1014. | 1.7 | 36 |
| 87 | Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1855-1861. | 0.6 | 36 |
| 88 | Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: Sequence non-specific recombination between the pml and rara genes within identical short stretches. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 37-44. | 1.5 | 35 |
| 89 | Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. <i>European Journal of Haematology</i> , 2005, 74, 418-423. | 1.1 | 35 |
| 90 | A Single Minor Histocompatibility Antigen Encoded by UGT2B17 and Presented by Human Leukocyte Antigen-A*2902 and -B*4403. <i>Transplantation</i> , 2007, 83, 1242-1248. | 0.5 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, S27-S30. | 1.1 | 34 |
| 92 | Expression of $CD56$ is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. <i>Cancer Science</i> , 2014, 105, 97-104. | 1.7 | 34 |
| 93 | Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. <i>Oncotarget</i> , 2016, 7, 47018-47032. | 0.8 | 34 |
| 94 | BCR-ABL independent and RAS-RAF-MAPK pathway dependent form of imatinib resistance in Philadelphia positive acute lymphoblastic leukemia cell line with activation of EphB4. <i>European Journal of Haematology</i> , 2010, 84, 229-238. | 1.1 | 33 |
| 95 | Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. <i>International Journal of Hematology</i> , 2012, 96, 84-93. | 0.7 | 33 |
| 96 | A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations. <i>Clinical Cancer Research</i> , 2007, 13, 4575-4582. | 3.2 | 32 |
| 97 | Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. <i>International Journal of Hematology</i> , 2011, 93, 66-73. | 0.7 | 31 |
| 98 | Genes for thrombopoietin and c-mpl are not responsible for familial thrombocythaemia: a case study. <i>British Journal of Haematology</i> , 1998, 100, 383-386. | 1.2 | 30 |
| 99 | B-cell precursors differentiated from cord blood CD34+ cells are more immature than those derived from granulocyte colony-stimulating factor-mobilized peripheral blood CD34+ cells. <i>Immunology</i> , 2001, 104, 410-417. | 2.0 | 28 |
| 100 | Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of $CDX2$ and $IDH1/2$ mutations. <i>Blood</i> , 2022, 139, 1850-1862. | 0.6 | 28 |
| 101 | Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. <i>Leukemia</i> , 2019, 33, 358-370. | 3.3 | 27 |
| 102 | SFK-STAT Pathway: An Alternative and Important Way to Malignancies. <i>Annals of the New York Academy of Sciences</i> , 2006, 1086, 213-222. | 1.8 | 26 |
| 103 | Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. <i>International Journal of Hematology</i> , 2010, 91, 276-283. | 0.7 | 26 |
| 104 | Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. <i>International Journal of Hematology</i> , 2008, 87, 144-151. | 0.7 | 25 |
| 105 | Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2009, 89, 3-13. | 0.7 | 25 |
| 106 | Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. <i>Leukemia Research</i> , 2000, 24, 349-352. | 0.4 | 24 |
| 107 | Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2008, 81, 454-460. | 1.1 | 24 |
| 108 | De novo diffuse large B-cell lymphoma with a $CD20$ immunohistochemistry positive and flow cytometry negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity. <i>Cancer Science</i> , 2014, 105, 35-43. | 1.7 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | <sc>SPIB</sc> is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the <sc>PI</sc>3K<sc>AKT</sc> pathway. <i>Cancer Science</i> , 2016, 107, 1270-1280. | 1.7 | 22 |
| 110 | Cytogenetic characterization of a T-cell line, ATN-1, derived from adult T-cell leukemia cells. <i>Cancer Genetics and Cytogenetics</i> , 1988, 34, 77-88. | 1.0 | 21 |
| 111 | Efficacy and safety of human adipose tissue-derived mesenchymal stem cells for supporting hematopoiesis. <i>International Journal of Hematology</i> , 2012, 96, 295-300. | 0.7 | 21 |
| 112 | Lack of Association between Intact/Deletion Polymorphisms of the APOBEC3B Gene and HIV-1 Risk. <i>PLoS ONE</i> , 2014, 9, e92861. | 1.1 | 21 |
| 113 | A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: Consistent chromosomal abnormalities and temporary C-MYC gene amplification. <i>Cancer Genetics and Cytogenetics</i> , 1998, 100, 21-24. | 1.0 | 19 |
| 114 | Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study. <i>Haematologica</i> , 2011, 96, 174-176. | 1.7 | 19 |
| 115 | Phase II study of imatinib-based chemotherapy for newly diagnosed <i>BCR<sc>ABL</i>-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 367-374. | 2.0 | 19 |
| 116 | Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. <i>Annals of Hematology</i> , 2019, 98, 83-91. | 0.8 | 19 |
| 117 | Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 624-636. | 2.5 | 19 |
| 118 | Phenylarsine Oxide (PAO) More Intensely Induces Apoptosis in Acute Promyelocytic Leukemia and As2O3-Resistant APL Cell Lines than As2O3 by Activating the Mitochondrial Pathway. <i>Leukemia and Lymphoma</i> , 2004, 45, 987-995. | 0.6 | 18 |
| 119 | CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. <i>Experimental Hematology</i> , 2012, 40, 724-737.e2. | 0.2 | 18 |
| 120 | Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2018, 103, e522-e526. | 1.7 | 17 |
| 121 | Expression cloning of oligomerization-activated genes with cell-proliferating potency by pseudotype retrovirus vector. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 920-926. | 1.0 | 16 |
| 122 | FLT3<sc>ITD regulates leukaemia cell adhesion through $\alpha 4 \beta 1$ integrin and Pyk2 signalling. <i>European Journal of Haematology</i> , 2011, 86, 191-198. | 1.1 | 16 |
| 123 | Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. <i>International Journal of Hematology</i> , 2012, 95, 409-419. | 0.7 | 16 |
| 124 | Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: A retrospective analysis of <sc>JALSG</sc>-<sc>APL</sc>97. <i>Cancer Science</i> , 2013, 104, 1339-1345. | 1.7 | 16 |
| 125 | Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity. <i>Oncogene</i> , 2019, 38, 2263-2274. | 2.6 | 16 |
| 126 | Molecular Heterogeneity of the PML Gene Rearrangement in Acute Promyelocytic Leukemia: Prevalence and Clinical Significance. <i>Japanese Journal of Cancer Research</i> , 1993, 84, 257-264. | 1.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2018, 107, 201-210. | 0.7 | 15 |
| 128 | Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. <i>Supportive Care in Cancer</i> , 2018, 26, 4187-4198. | 1.0 | 15 |
| 129 | Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. <i>Annals of Hematology</i> , 2020, 99, 2787-2800. | 0.8 | 15 |
| 130 | Diversity of Cellular Molecules in Human Cells Detected by Monoclonal Antibodies Reactive with c-myc Proteins Produced in <i>Escherichia coli</i> . <i>Japanese Journal of Cancer Research</i> , 1989, 80, 747-753. | 1.7 | 14 |
| 131 | Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. <i>European Journal of Haematology</i> , 2016, 97, 278-287. | 1.1 | 14 |
| 132 | Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 1-11. | 1.0 | 13 |
| 133 | FLT3 Mutations in Acute Myeloid Leukemia. , 2006, 125, 189-198. | | 12 |
| 134 | A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. <i>International Journal of Hematology</i> , 2011, 93, 237-242. | 0.7 | 12 |
| 135 | Sustained Remission after Rituximab-containing Chemotherapy for Intravascular Large B-cell Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2008, 48, 25-28. | 0.3 | 12 |
| 136 | Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography. <i>Scientific Reports</i> , 2018, 8, 4008. | 1.6 | 11 |
| 137 | Molecular cloning of the breakpoint of t(11;22)(q23;q11) chromosome translocation in an adult acute myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 1996, 92, 687-691. | 1.2 | 10 |
| 138 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5472-5477. | 1.0 | 10 |
| 139 | The demarcation between younger and older acute myeloid leukemia patients: A pooled analysis of 3 prospective studies. <i>Cancer</i> , 2013, 119, 3326-3333. | 2.0 | 10 |
| 140 | Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. <i>Annals of Hematology</i> , 2018, 97, 73-81. | 0.8 | 10 |
| 141 | Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021, 5, e617. | 1.2 | 10 |
| 142 | A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH gene. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 31-35. | 1.0 | 9 |
| 143 | Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG) AML206 study. <i>Cancer Science</i> , 2011, 102, 1358-1365. | 1.7 | 9 |
| 144 | Increased but highly dispersed levels of plasma glycofibrinogen in patients with disseminated intravascular coagulation. <i>European Journal of Haematology</i> , 1996, 56, 173-177. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 685-688. | 0.4 | 8 |
| 146 | Article. <i>Journal of Biochemistry</i> , 1997, 121, 550-559. | 0.9 | 7 |
| 147 | Phase I trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. <i>International Journal of Hematology</i> , 2012, 96, 485-491. | 0.7 | 7 |
| 148 | Establishment of a Stroma-Dependent Human Acute Myelomonocytic Leukemia Cell Line, NAMO-2, with FLT3 Tandem Duplication. <i>International Journal of Hematology</i> , 2006, 84, 328-336. | 0.7 | 6 |
| 149 | Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2008, 49, 2359-2364. | 0.6 | 6 |
| 150 | ZNF 384 fusion proteins have high affinity for the transcriptional coactivator EP 300 and aberrant transcriptional activities. <i>FEBS Letters</i> , 2019, 593, 2151-2161. | 1.3 | 6 |
| 151 | Phase II study of FLAGM (fludarabine+high-dose cytarabine+granulocyte colony-stimulating) Tj ETQq1 1 0.784314 <i>Hematology</i> , 2019, 109, 418-425. | 0.7 | 5 |
| 152 | Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature. <i>Cancers</i> , 2020, 12, 1444. | 1.7 | 5 |
| 153 | Production of a truncated human c-mycprotein which binds to DNA. <i>FEBS Letters</i> , 1988, 240, 49-54. | 1.3 | 4 |
| 154 | Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 65, 34-41. | 0.4 | 4 |
| 155 | Developing Target Therapy Against Oncogenic Tyrosine Kinase in Myeloid Maliganacies. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 331-337. | 0.9 | 3 |
| 156 | Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3 internal tandem duplication AML: The JALSG AML209 FLT3 SCT study. <i>Cancer Science</i> , 2020, 111, 2472-2481. | 1.7 | 3 |
| 157 | A Phase III Study of New Synthetic Retinoid Tamibarotene (Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL): Japan Adult Leukemia Study Group (JALSG) APL204 Study. <i>Blood</i> , 2012, 120, 410-410. | 0.6 | 3 |
| 158 | Leukemia Relapse Reconsidered from the Molecular Aspect. <i>Leukemia and Lymphoma</i> , 2000, 37, 527-534. | 0.6 | 1 |
| 159 | Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. <i>International Journal of Oncology</i> , 2007, , . | 1.4 | 1 |
| 160 | Tamibarotene for the treatment of acute promyelocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 961-969. | 0.5 | 1 |
| 161 | Acetylation of PML Plays a Key Role in Histone Deacetylase Inhibitor-Mediated Apoptosis through Enhanced PML Sumoylation.. <i>Blood</i> , 2007, 110, 4164-4164. | 0.6 | 1 |
| 162 | 'Editors' Choice' How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. <i>Nagoya Journal of Medical Science</i> , 2020, 82, 151-160. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Retention but Significant Reduction of BCR-ABL Transcript in Hematopoietic Stem Cells in Chronic Myelogenous Leukemia after Imatinib Therapy.. Blood, 2008, 112, 2116-2116. | 0.6 | 0 |